Head-to-Head: which MS drug works better in the real world?
NCT ID NCT07566988
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at over 2,600 people with multiple sclerosis to compare two drugs: Kesimpta and Ocrevus. Researchers used insurance claims data to see which drug led to fewer relapses and lower healthcare costs. The goal is to help patients and doctors choose the best treatment based on real-world results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ofatumumab (Kesimpta) and Ocrelizumab (Ocrevus)
- What this could lead to
- If results show one drug is clearly better, it could help doctors choose the most effective treatment for multiple sclerosis patients.
- What could go wrong
- This is a retrospective study using insurance claims, not a controlled trial, so results may be biased or miss important differences. It does not prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?